Algeta has successfully combined cutting-edge research with commercial know-how to create a product that has been designed to be easy-to-use for the patient, the administering clinician, a facility offering treatment, and the shipping companies set to distribute the medicine worldwide.
Algeta’s founders brought a mix of medical oncology and nuclear chemistry expertise, taking a very methodical approach to research. Analyzing the periodic table, looking for certain properties, their insight during development set Algeta on a course that it is still on today.
Based on the theory that alpha-emission could kill cancer cells, Algeta’s co-founders analyzed potential emitters. One of these was radium-223, which has similar properties to calcium and in turn seeks to solve a highly complex biological problem by targeting the chemistry of bone building.
In order to get from concept to commercialization of its product, Algeta has benefited from an active and influential Board of Directors. As the Company became more international, the Board has evolved geographically alongside it, gaining competencies in oncology, clinical development and business development.
"For many biotechs, there are often many twists and turns before you get to the target. For Algeta, it has been a relatively straight line"